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modifier, mast cell stabilizer, xanthine derivative, or a
long acting beta agonist); or one prescription for an
asthma controller and one or more prescriptions for a
short acting beta-agonist. Patients also had to be full year
members of the MCO. Patients with a diagnosis of
chronic obstructive lung disease were excluded. RE-
SULTS: A total of 351,140 persons were continuously
enrolled in the MCO during 1999. A total of 8,051 per-
sons were identified as having asthma (2.3% of the MCO
enrollees), with 43% being male. Persons under 18 years
of age comprised 28.8% of persons with asthma. Median
pharmacy costs were $472, median medical costs were
$483, and median total health care costs were $1199 for
this population. CONCLUSIONS: Asthma appears to af-
fect a significant number of enrollees within this MCO,
with persons less than 18 years of age representing al-
most 29% of the treated patients. Health care costs in
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OBJECTIVES: The objective of this study is to determine
the factors that influence satisfaction with non-sedating
antihistamines (NSA) among people who suffer from al-
lergies/hay fever. METHODS: An online survey was con-
ducted in September, 2000 on respondents who had been
told by a health care professional that they suffer from al-
lergies/hay fever and were recently (within 12 months)
prescribed one of three NSAs to relieve their symptoms.
The sample was weighted to ensure the generalizability of
the results. Satisfaction was measured according to the
medication’s ability to relieve side effects and control
symptoms from allergies/hay fever. A total of 4,081 re-
spondents were included in the analysis. RESULTS: (1)
The mean satisfaction score for the first time users (de-
fined as never having taken any medication for allergies/
hay fever) was higher than those who had used some
medication in the past (p  .01) (2) Of the respondents
who had a specific choice of medication in mind, those
who received their first choice medication had a higher
satisfaction score than those who did not (p  .01). (3)
The respondents who discussed their medication jointly
with their physician had a higher satisfaction score than
those whose doctor chose their medication for them (p 
.01). (4) Respondents who were not taking any over-the-
counter (OTC) medications reported higher satisfaction
scores than those who supplemented their NSA with
over-the-counter medications (p  .01). (5) Finally, re-
spondents who had never requested a prescription after
seeing an advertisement for any medication had a higher
satisfaction score than those who did. (p  .01) CON-
CLUSIONS: The data provides evidence to suggest that
past knowledge or experience with NSAs, patient prefer-
ence, and patient involvement in the treatment decision-
making process all play a role in determining satisfaction
with NSAs. Furthermore, both over-the-counter medica-
tion usage and direct-to-consumer advertising are likely
to influence how satisfied people are with their NSA.
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INTRODUCTION: Despite the high prevalence, mor-
bidity and mortality of COPD, remarkably little is
known about its impact on health care costs and utiliza-
tion of services. Information about health care utilization
and costs among patients with Chronic Obstructive Pul-
monary Disease (COPD) is needed to improve care and
for appropriate allocation of resources. OBJECTIVE:
The purpose of this study was to quantify the burden of
illness in Italy, in terms of both medical consumption and
lost productivity associated with COPD. METHODS:
Design: In 1998 an epidemiological study was conducted
in Italy. Retrospectively, from a community perspective,
we quantified COPD’s costs related both with health care
consumption and lost of productivity and/or school days.
Main Outcomes Measures: The main goal of the present
study was to evaluate economic outcomes in a cohort of
355,000 patients with current diagnosis of COPD. RE-
SULTS: As reported in previous studies, prevalence rate
for COPD in Italy is about 4,6% (2,637,000 subjects).
Among all COPD patients, 42,5% suffers from mild dis-
ease while 56,7% is affected by moderate-severe COPD,
on the basis of Flow Expiratory Value (FEV1) % of pre-
dicted criteria. The total cost of COPD we have quoted is
the sum of direct and indirect costs: it is worth US$18 bil-
lion, equal to US$6,843 average/patient/year. We have
not included intangible costs because they cannot be
quantified correctly as yet. CONCLUSIONS: COPD is
associated with significant both direct and indirect costs.
Previous studies reported that prevalence figures for
COPD based on recorded diagnoses are underestimated.
Notwithstanding, data from our study suggest that when
patients seek medical advice they were correctly diag-
nosed and treated. Education of patients will allow them
to take control of their disease and of costs related to
COPD.
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OBJECTIVE: Salmeterol, a long acting beta-2 agonist,
improves lung function and symptom control with twice
daily dosing in moderate-to-severe asthmatics. This in-
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vestigation was performed to determine whether the in-
troduction of salmeterol to moderate-to-severe asthmat-
ics in a Medicaid fee-for-service population reduces the
overall asthma related health care expenditures. METH-
ODS: The New Mexico Medicaid fee-for-service claims
database was searched between 1/1/94 and 12/31/98 to
identify both a salmeterol and control group. The inclu-
sion criteria for the salmeterol group were: patients re-
ceiving salmeterol, who were 66% compliant with salme-
terol therapy, had a diagnosis of asthma (ICD-9: 493.0,
493.1, 493.9), were 13 years of age or older, did not have
a diagnosis of COPD (ICD-9: 496.x) and must have been
Medicaid eligible for 2 consecutive years. In addition to
the above criteria for the salmeterol group, to be included
in the control group, patients must not have received sal-
meterol between 4/12/95 and 4/12/97 (around the me-
dian start date of salmeterol, 4/12/96), and in order to
match for severity must have received other asthma
maintenance medications. Patients meeting these criteria
for the salmeterol and control groups were 57 and 58, re-
spectively. ANCOVA were performed to compare costs
between the two groups controlling for baseline costs.
Average per patient benefit-cost ratios were calculated by
dividing total cost savings by increase in medication costs
for both groups. RESULTS: No significant difference ex-
isted among average per patient total health care expen-
ditures between the salmeterol and control groups ($2266
and $1955, respectively). Interestingly, in the salmeterol
group, total medication costs increased significantly (t 
7.895, p  0.000) while total health care costs de-
creased, although not significantly. The average per pa-
tient benefit-cost ratio for the salmeterol group was
0.061 ($41/$668). CONCLUSION: Introduction of sal-
meterol in the New Mexico Medicaid fee-for-service pop-
ulation did not significantly reduce total asthma related
health care costs.
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OBJECTIVES: To compare effectiveness of compliance
on health care utilization between montelukast and stan-
dard therapy (inhaled corticosteroid—ICS) patients. Indi-
cators for health care resource use include drug use, ER
visits, and total charges. METHODS: Retrospective co-
hort analysis using LifeLink employer claims database of
1.6 million Americans. ANOVA models examined health
care resource use of montelukast and ICS patients in six
months prior (pre-period) and six month following (post-
period) new treatment of interest adjusting for age, gen-
der, region, plan type, and prescriber specialty. RE-
SULTS: The study cohort consisted of 3,775 montelukast
patients and 7,331 ICS patients. Average compliance, de-
fined as medication possession ratio, of montelukast pa-
tients (63%) was significantly greater (p  0.001) than
that of ICS patients (31%). Montelukast patients were
more likely to receive short-acting beta-agonist therapy in
pre-period than ICS patients (p  0.001), which suggests
more severe patients in montelukast group, but there was
no significant difference between two groups in post-
period (p  0.854). Among patients with concomitant
methylxanthine therapy, montelukast patients had more
days of methylxanthine therapy than ICS in pre-period
(p  0.001), but there was no significant difference in
post-period (p  0.130). For patients with at least one
asthma-related ER visit, montelukast patients had more
ER visits per patient than ICS patients in pre-period (p 
0.010), but no significant difference was noted in post-
period (p  0.325). Average total charges for montelukast
were higher than for ICS patients in both pre-period (p 
0.001) and post-period (p  0.001). CONCLUSIONS:
Compliance with montelukast treatment was markedly
better than with ICS therapy. Initially, montelukast pa-
tients were higher resource users than ICS patients. Dur-
ing six months treatment with montelukast, some health
care resources used decreased to the level of ICS patients.
Results suggest that markedly improved compliance of
montelukast decreased asthma-related health care utiliza-
tion, however total charges for montelukast patients re-
mained higher than for ICS patients.
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Preliminary pharmacoeconomic analyses suggest that
levalbuterol (LEV) therapy is associated with decreased
outpatient asthma health care costs. OBJECTIVE: Exam-
ine treatment costs in asthma patients stratified by the
number of prescribed controller medications (CM), an in-
dex of asthma severity. METHODS: Claims data on pa-
tients prescribed LEV and RAC were obtained from the
PharMetrics Integrated Outcomes Database. Age- and
sex-matched samples of patients initiating therapy with
LEV or RAC (no prescriptions for either agent in prior 6
months) were selected and their asthma-related charges
were assessed over 6 months following the initial pre-
scription. RESULTS: 544 LEV-treated patients were
identified and matched to 544 RAC-treated patients.
62% of RAC patients previously received no CM, 20%
had 1 CM, and 18% had 1 CM. Following RAC treat-
ment 30% had 1 CM and 29% had 1 CM. Use of leu-
kotriene modifiers increased from 8% to 14% and corti-
costeroid use increased from 33% to 46%. Although
